Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06079164 · ClinicalTrials.gov registry record · Phase 1
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
A Phase 1 study of Relapsed/Refractory Large B-cell Lymphoma, sponsored by Kite, A Gilead Company.
- Active
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 11
- Study locations
NCT06079164 is a Phase 1 study of Relapsed/Refractory Large B-cell Lymphoma that is active but no longer recruiting, run by Kite, A Gilead Company. The registered enrollment target is 39 participants. The trial reports 11 study locations across 9 states.
The verdict
NCT06079164, a Phase 1 study of Relapsed/Refractory Large B-cell Lymphoma, is active but no longer recruiting, sponsored by Kite, A Gilead Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in participants with relapsed or refractory large B-cell lymphoma (r/rLBCL). The goal of Phase 1b of this clinical study is learn about the effectiveness of the recommended dose of KITE-197 in participants with r/r LBCL. The primary objectives of this study are: Phase 1a: To evaluate the safety of KITE-197 in participants with r/r LBCL and determine the target dose level for Phase 1b. Phase 1b: To evaluate the efficacy of KITE-197 in participants with r/r LBCL as measured by the complete remission (CR) rate.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG KITE-197
Study Locations (11)
Other
- Cross Cancer Institute - Edmonton
- QEII Health Sciences Centre - Halifax
- Jewish General Hospital - Montreal
Florida
- Sylvester Comprehensive Cancer Center - Miami
Illinois
- University of Chicago Medical Center - Chicago
Tennessee
- Henry-Joyce Cancer Clinic - Nashville
Texas
- St. David's South Austin Medical Center - Austin
Washington
- Swedish Cancer Institute - Seattle
New South Wales
- Royal Prince Alfred Hospital - Camperdown
Queensland
- Royal Brisbane and Women's Hospital - South Brisbane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06079164
The ClinicalTrials.gov registry entry for NCT06079164 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Large B-cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT06079164 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Other, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06079164 about?
NCT06079164 is a clinical study titled "Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma". This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in participants with relapsed or refractory large B-cell lymphoma (r/rLBCL). The goal of Phase 1b of this clinical st...
What is the current status of trial NCT06079164?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2023-11-09. Estimated completion is 2026-07.
What conditions does trial NCT06079164 study?
This clinical trial studies the following conditions: Relapsed/Refractory Large B-cell Lymphoma.
What interventions are being tested in trial NCT06079164?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), KITE-197 (DRUG).
Who is sponsoring clinical trial NCT06079164?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06079164 being conducted?
This trial has 11 study locations across Florida, Illinois, Tennessee, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.